Skip to content
Study details
Enrolling now

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

University of Chicago
NCT IDNCT04361708ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

54

Study length

about 7.1 years

Ages

18+

Locations

1 site in IL

What this study is about

Researchers are testing the safety of a treatment combining irinotecan with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel. The trial will involve adults who have adenocarcinoma, gastroesophageal junction adenocarcinoma, or pancreatic adenocarcinoma.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take 5-Fluorouracil
  • 2.Take Docetaxel
  • 3.Take Irinotecan
  • +2 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), docetaxel, irinotecan, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), oxaliplatin

Drug routes

infusion, injection (Injection)

Endpoints

Secondary: Overall Response Rate, Overall survival rate, Progression free survival rate